Becton Dickinson and Co logo

Becton Dickinson and Co (BDX)

Market Closed
14 Feb, 20:00
NYSE NYSE
$
224. 80
-0.21
-0.09%
After Hours
$
224. 80
0 0%
65.24B Market Cap
- P/E Ratio
3.8% Div Yield
1,131,500 Volume
- Eps
$ 225.01
Previous Close
Day Range
224.78 227.45
Year Range
218.75 251.99
Earnings results expected in 75 days

Summary

BDX closed today lower at $224.8, a decrease of 0.09% from yesterday's close, completing a monthly decrease of -1.41% or $3.21. Over the past 12 months, BDX stock lost -1.41%.
BDX pays dividends to its shareholders, with the most recent payment made on Dec 31, 2024. The next estimated payment will be in In 1 month on Mar 31, 2025 for a total of $1.04.
The last earnings report, released on Jan 30, 2025, exceeded the consensus estimates by 0.44%. On average, the company has surpassed earnings expectations by 0.22%, based on the last three reports. The next scheduled earnings report is due on May 01, 2025.
The stock of the company had never split.
The company's stock is traded on 14 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track BDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

BDX Chart

Becton Dickinson and Co (BDX) FAQ

What is the stock price today?

The current price is $224.80.

On which exchange is it traded?

Becton Dickinson and Co is listed on NYSE.

What is its stock symbol?

The ticker symbol is BDX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 65.24B.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 01, 2025.

Has Becton Dickinson and Co ever had a stock split?

No, there has never been a stock split.

Becton Dickinson and Co Profile

Medical Instruments & Supplies Industry
Healthcare Sector
Mr. Thomas E. Polen Jr. CEO
NYSE Exchange
075887109 Cusip
United States Country
70,000 Employees
31 Dec 2024 Last Dividend
1 Apr 2022 Last Split
- IPO Date

Overview

Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.

Products and Services

  • BD Medical:

    This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.

  • BD Life Sciences:

    In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.

  • BD Interventional:

    BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.

Contact Information

Address: 1 Becton Drive
Phone: 201 847 6800